On October 24, 2024, Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") announced a strategic partnership with Porton Pharma Solutions Ltd. ("Porton") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton Pharma Solutions; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center；Dr. Fang Xin, Senior Director of Non-clinical Pharmacology BU at InnoStar；and Ms. Zhao Jie, Marketing Associate Director at InnoStar.
![]()
During the signing ceremony, Dr. Chang Yan, President of InnoStar, emphasized the company's long-standing commitment to providing non-clinical R&D services in the innovative drug sector. InnoStar aims to establish a high-quality, one-stop international service platform for comprehensive evaluation of innovative drugs. Dr. Yan encouraged industry peers to developing win-win cooperation to explore cutting-edge technologies and innovative methodologies in pharmaceutical R&D, integrate resources, expand markets collaboratively, promote high-quality growth in the innovative drug industry, and cultivate a virtuous cycle within the industry ecosystem. The strategic partnership with Porton, a leading global CDMO enterprise, signifies not just a close business alliance but also a profound ideological synergy. We aspire to collaborate further to establish a comprehensive mechanism for market resource sharing and business collaboration, fostering deep integration and mutual benefit. Together, we aim to provide end-to-end, high-quality, and efficient services to clients, explore new opportunities in domestic and international markets, and further enhance both parties' competitiveness in global pharmaceutical R&D.
At today's signing ceremony, Mr. Ju Nianfeng, Chairman and CEO of Porton, emphasized the company's commitment to its mission of "Enabling the public’s early access to good medicines" by maintaining a customer-centric approach and providing innovative, reliable global CDMO solutions. Our services have expanded from small molecule drugs to include new modalities such as peptides, oligonucleotide drugs, and conjugated drugs. Through technological innovation and a commitment to open, win-win collaborations, we continue to advance the pharmaceutical industry. The collaboration with InnoStar marks a significant step forward in our pursuit of resource sharing and model innovation. InnoStar's extensive experience in non-clinical research services for innovative drugs, combined with Porton's expertise and resources in the CDMO field, will enhance our service capabilities and efficiency, accelerate the drug development process, and create greater value and opportunities for our clients. Furthermore, this partnership will strengthen our presence in the global market and guide us to a new stage of development.![]()
![]()
Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar), was established in 2010. As a leading contract research organization, we adhere to the core values of “Science orientated, Quality first, Integrity & dedication, Win-win cooperation”, and strive for innovative and reputational services with high quality and excellence. Over the past decade, InnoStar has successfully passed GLP inspections by various national and international authorities, including US FDA, and received the GLP certification from the National Medical Products Administration (NMPA), OECD GLP certification, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. Our business scope covers screening and discovery services, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, biomarkers and translational research. InnoStar was listed on the STAR InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710).
![]()
Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, etc.) from pre-clinical to commercialization. As of June 30, 2024, we have a proven record for the delivery of more than 3500 projects and established cooperation with more than 1000 global clients. With our 4300+ skilled employees working across 20+ sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public’s early access to good medicines. Porton is publicly listed on the Shenzhen Stock Exchange (Ticker: 300363).
